These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 20400929)

  • 21. Unravelling the role of denosumab in prostate cancer.
    Aragon-Ching JB
    Lancet; 2011 Mar; 377(9768):785-6. PubMed ID: 21353698
    [No Abstract]   [Full Text] [Related]  

  • 22. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.
    Body JJ; Facon T; Coleman RE; Lipton A; Geurs F; Fan M; Holloway D; Peterson MC; Bekker PJ
    Clin Cancer Res; 2006 Feb; 12(4):1221-8. PubMed ID: 16489077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endocrine therapy and bone loss in breast cancer: time to close in the RANK(L)?
    Lønning PE
    J Clin Oncol; 2008 Oct; 26(30):4859-61. PubMed ID: 18725646
    [No Abstract]   [Full Text] [Related]  

  • 24. [Treatment of bone metastasis with anti-RANKL antibody].
    Chayahara N; Minami H
    Clin Calcium; 2011 Aug; 21(8):1217-22. PubMed ID: 21814028
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New developments for treatment and prevention of bone metastases.
    Body JJ
    Curr Opin Oncol; 2011 Jul; 23(4):338-42. PubMed ID: 21519257
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted therapies: denosumab--a new option for solid tumors metastatic to bone.
    Saylor PJ
    Nat Rev Clin Oncol; 2011 Jun; 8(6):322-4. PubMed ID: 21556026
    [No Abstract]   [Full Text] [Related]  

  • 27. [Anti-RANKL antibody for treatment of patients with bone metastasis from breast cancer].
    Takahashi S
    Gan To Kagaku Ryoho; 2012 Jan; 39(1):89-94. PubMed ID: 22241358
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases.
    Lipton A; Steger GG; Figueroa J; Alvarado C; Solal-Celigny P; Body JJ; de Boer R; Berardi R; Gascon P; Tonkin KS; Coleman R; Paterson AH; Peterson MC; Fan M; Kinsey A; Jun S
    J Clin Oncol; 2007 Oct; 25(28):4431-7. PubMed ID: 17785705
    [TBL] [Abstract][Full Text] [Related]  

  • 29. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer.
    Van Poznak CH; Temin S; Yee GC; Janjan NA; Barlow WE; Biermann JS; Bosserman LD; Geoghegan C; Hillner BE; Theriault RL; Zuckerman DS; Von Roenn JH;
    J Clin Oncol; 2011 Mar; 29(9):1221-7. PubMed ID: 21343561
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New strategies to prevent and manage bone complications in cancer.
    Lipton A
    Clin Adv Hematol Oncol; 2011 Jan; 9(1):42-4. PubMed ID: 21326145
    [No Abstract]   [Full Text] [Related]  

  • 31. Safety and efficacy of denosumab in giant-cell tumour of bone.
    Kyrgidis A; Toulis K
    Lancet Oncol; 2010 Jun; 11(6):513-4. PubMed ID: 20522379
    [No Abstract]   [Full Text] [Related]  

  • 32. Denosumab in osteoporosis and oncology.
    Burkiewicz JS; Scarpace SL; Bruce SP
    Ann Pharmacother; 2009 Sep; 43(9):1445-55. PubMed ID: 19622756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Denosumab and the current status of bone-modifying drugs in breast cancer.
    Lee BL; Higgins MJ; Goss PE
    Acta Oncol; 2012 Feb; 51(2):157-67. PubMed ID: 22150116
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Denosumab: a breakthrough in treatment of giant-cell tumour of bone?
    Balke M; Hardes J
    Lancet Oncol; 2010 Mar; 11(3):218-9. PubMed ID: 20149737
    [No Abstract]   [Full Text] [Related]  

  • 35. [Anti-RANKL antibody for the management of bone metastasis].
    Yoneda T
    Gan To Kagaku Ryoho; 2011 Sep; 38(9):1439-45. PubMed ID: 21918338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure.
    Body JJ; Lipton A; Gralow J; Steger GG; Gao G; Yeh H; Fizazi K
    J Bone Miner Res; 2010 Mar; 25(3):440-6. PubMed ID: 19653815
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of denosumab for the treatment of bone metastases in patients with advanced cancer.
    Kurata T; Nakagawa K
    Jpn J Clin Oncol; 2012 Aug; 42(8):663-9. PubMed ID: 22701037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid.
    Martin M; Bell R; Bourgeois H; Brufsky A; Diel I; Eniu A; Fallowfield L; Fujiwara Y; Jassem J; Paterson AH; Ritchie D; Steger GG; Stopeck A; Vogel C; Fan M; Jiang Q; Chung K; Dansey R; Braun A
    Clin Cancer Res; 2012 Sep; 18(17):4841-9. PubMed ID: 22893628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety considerations for use of bone-targeted agents in patients with cancer.
    Mortimer JE; Pal SK
    Semin Oncol; 2010 Jun; 37 Suppl 1():S66-72. PubMed ID: 20682374
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging therapeutic targets in osteoncology.
    Santini D; Pantano F; Vincenzi B; Tonini G
    Oncology; 2011; 80(3-4):223-4. PubMed ID: 21734412
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.